Cargando…
P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)
Autores principales: | Tembhare, Prashant, Raj, Simpy, Ghogale, Sitaram, Deshpande, Nilesh, Girase, Karishma, Chatterjee, Gaurav, Rajpal, Sweta, Patkar, Nikhil, Narula, Gaurav, Bagal, Bhausaheb, Jain, Hasmukh, Sengar, Manju, Banavali, Shripad, Shetty, Dhanlaxmi, Dhamne, Chetan, Khanka, Twinkle, Varghese, Steffi, Jasdanwala, Shaista, Khattry, Navin, G Subramanian, Papagudi, Gujral, Sumeet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428408/ http://dx.doi.org/10.1097/01.HS9.0000968352.94316.c1 |
Ejemplares similares
-
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
por: Tembhare, Prashant Ramesh, et al.
Publicado: (2020) -
Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin’s Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India
por: Tembhare, Prashant R., et al.
Publicado: (2022) -
Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients
por: Tembhare, Prashant R., et al.
Publicado: (2020) -
P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
por: Bhide, Aniket, et al.
Publicado: (2023) -
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
por: Patkar, Nikhil, et al.
Publicado: (2021)